Peptide Ile-Pro-Pro for Oral Brain Function Improvement
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic drugs for Alzheimer's disease and amnesia, such as acetylcholinesterase inhibitors, have hepatotoxicity and strong side effects, are costly, and require high doses for oral administration, while existing peptides show limited effectiveness and unknown actions in improving brain function.
Innovation Solution
A composition comprising the peptide Ile-Pro-Pro or Leu-Pro-Pro, administered orally, which is chemically synthesized or derived from natural products, and used to protect against or reduce the risk of amnesia or dementia by improving brain function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If acetylcholinesterase inhibitors are administered to treat Alzheimer's disease, then brain function improvement is achieved, but hepatotoxicity and strong side effects occur
Solution Approach 1:
The patent replaces expensive, long-term therapeutic drugs with a peptide composition that can be administered orally in smaller doses. The peptide Ile-Pro-Pro or Leu-Pro-Pro acts as a temporary, non-toxic intervention that improves brain function without the harmful side effects of conventional acetylcholinesterase inhibitors, aligning with the principle of using safe, short-term solutions instead of persistent harmful treatments.
Solution Approach 2:
The patent changes the chemical structure and administration method by using a peptide composition that can be orally administered, rather than traditional intravenous or oral drugs that require high doses. This parameter change in the substance type and delivery method reduces toxicity while maintaining therapeutic effectiveness.
2Duration of action of stationary object
If acetylcholinesterase inhibitors are used for extended period, then Alzheimer's disease treatment is maintained, but cost increases and safety risks accumulate
Solution Approach 1:
The peptide composition offers a safer alternative that can be administered for extended periods without accumulating toxicity. Unlike acetylcholinesterase inhibitors that require monitoring for liver damage over time, the peptide provides a safer long-term solution with lower cost and reduced monitoring requirements.
3Reliability
If existing peptides are administered orally to improve brain function, then some effect is observed, but large doses are required reducing oral ingestibility
Solution Approach 1:
The patent optimizes the peptide sequence and structure to improve bioavailability and reduce the required dose. By carefully selecting the amino acid sequence (Ile-Pro-Pro or Leu-Pro-Pro) and controlling the peptide's physical and chemical properties, the invention achieves effective brain function improvement at much lower doses than existing peptides, making oral administration practical.
Data Source
Figure 1
Figure 2
AI summary
The present invention provides a composition which may be ingested orally in a small dose for the purpose of improving brain function, and a method for improving brain function. The present invention is a composition for improving brain function, the composition comprising, as an active ingredient, Xaa-Pro-Pro (wherein Xaa represents Ile, Leu or Ser).